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0Analysis of the haptoglobin binding region on
the apolipoprotein A-I-derived P2a peptide{
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Bernadetta Maresca,c Luisa Ciglianoc and Luca D. D’Andreab*Apolipoprotein A-I (ApoA-I) is the main protein component of the high density lipoproteins and it plays an important role in the
reverse cholesterol transport. In particular, it stimulates cholesterol efﬂux fromperipheral cells toward liver and activates the enzyme
lecithin-cholesterol acyltransferase (LCAT). Haptoglobin (Hpt), a plasma a2-glycoprotein belonging to the family of acute-phase
proteins, binds to ApoA-I inhibiting the stimulation of the enzyme LCAT. Previously, we reported that a synthetic peptide, P2a, binds
to and displaces Hpt from ApoA-I restoring the LCAT cholesterol esteriﬁcation activity in the presence of Hpt. Here, we investigate
the molecular determinants underlining the interaction between Hpt and P2a peptide. Analysis of truncated P2a analogs showed
that P2a sequence can only be slight reduced in length at the N-terminal to preserve the ability of binding to Hpt. Binding assays
showed that charged residues are not involved in Hpt recognition; actually, E146A and D157A substitutions increase the binding
afﬁnity to Hpt. Biological characterization of the corresponding P2a peptide analogs, Apo146 and Apo157, showed that the two
peptides interfere with Hpt binding to HDL and aremore effective than P2a peptide in rescue LCAT activity fromHpt inhibition. This
result suggests novel hints to design peptides with anti-atherogenic activity. Copyright © 2013 European Peptide Society and John
Wiley & Sons, Ltd.
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Apolipoprotein A-I (ApoA-I), the major protein component of the
high density lipoproteins (HDL), plays an important role in the
reverse cholesterol transport (RCT). It stimulates the efﬂux of choles-
terol from peripheral cells toward liver and activates the enzyme
lecithin-cholesterol acyltransferase (LCAT; EC 2.3.1.43) to convert
cell-derived cholesterol into cholesteryl ester for HDL mediated
transport to liver for excretion [1]. ApoA-I is composed of 243 amino
acids organized in ten a-helix segments divided in eight 22-mer and
two 11-mer repeats with a predominant amphipathic character. The
structure of ApoA-I has been deeply investigated using several
experimental techniques. These studies showed that ApoA-I is a
dynamic protein characterized by structural plasticity depending
on the lipid composition of HDL [2–8].
We previously reported that ApoA-I binds to Haptoglobin (Hpt)
[9,10]. Hpt is a plasma a2-glycoprotein, mainly expressed in the liver,
belonging to the family of acute-phase proteins. Hpt binds free
Hemoglobin (Hb) with extremely high afﬁnity [11–13], and the
complex is then caught by macrophages and hepatocytes for
elimination from circulation [13,14]. In this way, Hpt prevents iron loss
and represents the primary defense mechanism against free Hb
[15,16]. Furthermore, Hpt protects ApoA-I against hydroxyl radicals,
thus saving the apolipoprotein function in physiological conditions
[17]. On the other hand, high levels of Hpt, as those circulating during
inﬂammation, impair ApoA-I stimulation of both LCAT [9,10] and
cholesterol uptake by hepatocytes [18]. Thereby, cholesterol removal
from peripheral cells would be hampered, suggesting that high
levels of Hpt, as present during the acute phase of inﬂammation,
may play a critical role in worsening vascular endothelial dysfunction
and accelerating atherosclerosis. Indeed, several studies have conﬁrmed
that high levels of Hpt are associated with increased risk of devel-
oping cardiovascular events or myocardial infarction [19–21].J. Pept. Sci. 2013; 19: 220–226Wemapped the Hpt binding site on ApoA-I region 141–164, which
overlaps with the ApoA-I domain required for LCAT stimulation [22].
This suggests that Hpt impairs LCAT activity by masking the stimula-
tory region of ApoA-I. Furthermore, we showed that a synthetic
peptide, P2a, reproducing the ApoA-I sequence 141–164, binds to
and displaces Hpt from ApoA-I on HDL surface [23]. The peptide
P2a was able to restore the LCAT cholesterol esteriﬁcation activity
in the presence of Hpt in vitro [23] and in vivo in an experimental
model of inﬂammation [24]. These results indicate that P2a effectively
targets the Hpt–HDL recognition surface and suggest that P2a could
be a promising candidate to modulate pharmaceutically the RCT.
In this context, we aim to investigate the molecular determinants
underlining the interaction between Hpt and P2a peptide. In this
work, we synthesized, characterized by CD spectroscopy and
analyzed the biological properties of a series of P2a peptide analogs
in order to address either the effect of peptide length and the role of
charged residues. Finally, we selected two single amino acid substitu-
tions which improved the biological activity of P2a.Copyright © 2013 European Peptide Society and John Wiley & Sons, Ltd.
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1Materials and Methods
Chemicals
Fmoc protected amino acids and coupling reagents were
purchased from Inbios (Naples, Italy). PAL-PEG PS (Peptide
Amide Linker – polyethylene glycol-polystyrene) resin was
obtained from Perseptive Biosystem GmbH (Hamburg, Germany).
Peptide synthesis solvents with the lowest water content (DMF,
NMP (N-Methyl-2-pyrrolidone), and DCM) and acetonitrile were
supplied by Romil (Cambridge, UK) and used without further puri-
ﬁcation; DIPEA, acetic anydride, piperidine, TIS (triisopropylsilane),
diethyl ether, and HPLC solvents were from Sigma-Aldrich
(Milan, Italy).
Biochemicals
Chemicals of the highest purity, fraction V BSA, human serum
albumin, cholesterol, human Hpt (mixed phenotypes: Hpt 1–1,
Hpt 1–2, and Hpt 2–2), rabbit anti-human Hpt IgG, goat anti-
rabbit horseradish peroxidase-conjugated, o-phenylenediamine,
Avidin-HRP, and molecular weight markers were purchased from
Sigma-Aldrich (Milan, Italy). Human HDL was from Merck Millipore
(Darmstadt, Germany). [1a,2a-3H] Cholesterol (45Ci/mmol) was
obtained from Perkin Elmer (Boston, USA). Polystyrene 96-wells
plates from Nunc (Roskilde, Denmark) and Sil-G plates for thin-layer
chromatography (0.25mm thickness) of Macherey-Nagel (Düren,
Germany) were used. Sephacryl S-200, Blue Sepharose 6 Fast Flow,
and CNBr-activated Sepharose were purchased from GE Healthcare
Europe GmbH (Milan, Italy).
Solid Phase Peptide Synthesis
Peptides were synthesized on PAL-PEG PS resin (0.42mmol/g)
using standard Fmoc/tBu chemistry. Fmoc deprotection was
performed washing the resin two times (7min) with a solution of
30% piperidine in DMF, coupling reactions were performed with
8 equiv of Fmoc-amino acid and 7.9 HBTU/HOBt, 16 eq DIPEA in
DMF for 45min at room temperature, capping step (1 5min)
was performed with a solution of acetic anhydride (0.5M)/HOBt
(0.015M)/DIPEA (0.125M) in DMF. Each step was followed by
ﬁve washing with DMF for 1min. Peptides were biotinylated on
solid phase reacting the peptide Na amino group, after Fmoc
deprotection, with 2 equiv of N-(+)-biotinyl-6-aminocaproic acid
(Sigma-Aldrich, Milan, Italy), 2 equiv of HATU and 4 equiv of
DIPEA in DMF o.n. at room temperature under shaking.
Peptide cleavage was performed using TFA/TIS/H2O/EDT (94 : 1
: 2.5 : 2.5; v/v/v/v). Peptides were precipitated in cold ether and
liophilyzed.
Peptide Puriﬁcation and Analysis
Peptide puriﬁcations were carried out on a Shimadzu LC-8A,
equipped with an SPD-M10 AV detector, using a C18 column
Jupiter (250 10mm, 300 , 10mm; Phenomenex, Torrance, USA).
Peptide identiﬁcation was performed on the LC-MS Finnegan
Surverior Thermo C (Thermo Fisher Scientiﬁc, Waltham, USA)
equipped with an ESI source and single quadrupole mass
analyzer coupled to a Surveyor HPLC system (with photo diode
array detector) using a C18 column Jupiter (250 4.6mm, 300 ,
5 mm; Phenomenex, Torrance, USA). Peptide analytical charac-
terization was carried out on a Hewlett Packard HP1100 HPLC
equipped with UV detector using a C18 column JupiterJ. Pept. Sci. 2013; 19: 220–226 Copyright © 2013 European Peptide Society a(250 4.6mm, 300 , 5 mm; Phenomenex, Torrance, USA). Linear
gradients of CH3CN (0.1% TFA) in H2O (0.1% TFA) at a ﬂow
rate of 1ml/min were used in peptide analyses as reported
below (5-70-30: from 5% to 70% over 30min). All peptides were
afforded in high pure and homogenous forms as assessed by
analytical RP-HPLC (>95%-based chromatographic proﬁle revealed
at 210 nm).
Peptide P2a: MS m/z calcd 2756.3Da, found 2757.2Da, RP-HPLC
Rt = 13.4min (20-80-40); biotinylated MSm/z calcd, 3052.6Da, found
3050.6Da, RP-HPLC Rt = 16.0min (5-70-30).
Peptide Apo146: MS m/z calcd, 2700.9 Da, found 2704.2 Da,
RP-HPLC Rt = 17.1min (5-70-25); biotinylated MS m/z calcd,
2996.9 Da, found 2998.4Da, RP-HPLC Rt = 18.3min (5-70-25).
Peptide Apo147: MS m/z calcd 2700.9 Da, found 2698.6 Da,
RP-HPLC Rt = 17.0min (5-70-25); biotinylated MS m/z calcd
2996.9 Da, found 2997.5Da, RP-HPLC Rt = 24.6min (5-70-30).
Peptide Apo149: MS m/z calcd 2673.9 Da, found 2670.6 Da,
RP-HPLC Rt = 17.6min (5-70-25); biotinylated MS m/z calcd
2969.9 Da, found 2970.2Da, RP-HPLC Rt = 23.8min (5-70-30).
Peptide Apo150: MS m/z calcd 2714.9 Da, found 2711.1 Da,
RP-HPLC Rt = 16.8min (5-70-25); biotinylated MS m/z calcd
3010.9 Da, found 3010.1Da, RP-HPLC Rt = 24.8min (5-70-25).
Peptide Apo151: MS m/z calcd 2673.9 Da, found 2671.2 Da,
RP-HPLC Rt = 17.8min (5-70-25); biotinylated MS m/z calcd
2969.9 Da, found 2970.5Da, RP-HPLC Rt = 25.5min (5-70-30).
Peptide Apo153: MS m/z calcd 2673.9 Da, found 2670.8 Da,
RP-HPLC Rt = 17.4min (5-70-25); biotinylated MS m/z calcd
2969.9 Da, found 2970.5Da, RP-HPLC Rt = 22.5min (5-70-30).
Peptide Apo155: MS m/z calcd 2692.9 Da, found 2688.0 Da,
RP-HPLC Rt = 19.0min (5-70-30); biotinylated MS m/z calcd
2988.9 Da, found 2987.3Da, RP-HPLC Rt = 21.3min (5-70-30).
Peptide Apo157: MS m/z calcd 2714.9 Da, found 2712.2 Da,
RP-HPLC Rt = 17.0min (5-70-25); biotinylated MS m/z calcd
3011.0 Da; found 3009.6Da, RP-HPLC Rt = 23.0min (5-70-30).
Peptide Apo160: MS m/z calcd 2673.9 Da, found 2671.2 Da,
RP-HPLC Rt = 13.0min (5-60-8); biotinylated MS m/z calcd
2969.9 Da, found 2970.5Da, RP-HPLC Rt = 23.0min (5-70-30).
Peptide Apo162: MS m/z calcd 2692.9 Da, found 2692.6 Da,
RP-HPLC Rt = 18.1min (5-70-25); biotinylated MS m/z calcd
2988.9 Da, found 2987.3Da, RP-HPLC Rt = 23.1min (5-70-30).
Peptide Apo144-164: MS m/z calcd 2458.7Da, found 2459.9Da,
RP-HPLC Rt = 16.1min (5-70-25); biotinylated MS m/z calcd
2755.5Da, found 2756.8Da, RP-HPLC Rt = 16.5min (5-70-25).
Peptide Apo146-164: MS m/z calcd 2288.5Da, found 2288.9Da,
RP-HPLC Rt = 15.3min (5-70-25); biotinylated MS m/z calcd
2586.0Da, found 2586.0Da, RP-HPLC Rt = 15.3min (5-70-25).
Peptide Apo141-161: MS m/z calcd 2434.7Da, found 2433.3Da,
RP-HPLC Rt = 16.8min (5-70-25); biotinylated MS m/z calcd
2732.2Da, found 2732.9Da, RP-HPLC Rt = 16.8min (5-70-25).Circular Dichroism spectroscopy
Far-UV circular dichroism spectra were recorded on a J-715 spectro-
polarimeter (Jasco, Easton, USA), equipped with a PTC-423S/15
Peltier temperature controller, using a 0.1 cm quartz cell (Hellma,
Milan, Italy) in the range 190–260nm. Peptides (100–200mM) were
dissolved in 10mM phosphate buffer pH7.1 and variable volume
of TFE. Spectra were acquired at 20 C using a band width of 1nm,
a response time of 8 s, a data pitch of 0.5nm, and a scanning speed
of 10nm/min. Each spectrum has an average of three scans with the
background of the buffer solution subtracted. CD data werend John Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
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2expressed as molar residue ellipticity (θ). Spectra were processed
using the Spectra Manager software by Jasco.
Puriﬁcation of Hpt
Hpt was isolated from plasma of healthy subjects by a multi-step
puriﬁcation procedure, essentially according to Cigliano et al. [18].
Plasma proteins were fractionated by salting out in ammonium
sulfate, and the protein solution was then freed of salts by gel
ﬁltration with a column of Sephacryl S-200. Fractions containing
Hpt were pooled and further processed by afﬁnity chromatography
with a column of Blue Sepharose 6 Fast Flow. The column was
equilibrated with P-buffer (20mM Na2HPO4/ NaH2PO4 pH7.0) and
then loaded at 30ml/h ﬂow rate at room temperature. The material
not retained by the resin was collected, and then the column was
extensively washed with P-buffer, and ﬁnally eluted with 2M NaCl
in P-buffer. Hpt was further puriﬁed by afﬁnity chromatography
using a Sepharose resin coupled to anti-Hpt IgGs. The purity of
isolated Hpt was over 98%, as assessed by SDS-PAGE and densito-
metric analysis of Coomassie-stained bands. The molarity of each
Hpt phenotype was determined by measuring the protein concen-
tration as mg/ml [25] and calculating the molecular weight of the
monomer ab as previously described [26].
ELISA
ELISA was performed essentially as previously reported [23,27]. In
particular, experiments of peptides binding to Hpt were performed
incubating the wells with of 0.5mg of Hpt in 50ml of coating buffer
(7mM Na2CO3, 17mM NaHCO3, 1.5mM NaN3, pH9.6). After four
washes by TBS (130mM NaCl, 20mM Tris-HCl, pH7.4) containing
0.05% (v/v) Tween 20 (T-TBS) and four washes by high salt TBS
(500mM NaCl in 20mM Tris-HCl at pH7.4), the wells were blocked
with TBS (Tris-buffered saline) containing 0.5% BSA (1h, 37 C). The
wells were then incubated with 55ml of biotinylated peptide (0.3, 1,
3, or 10mM). Bound peptides were then incubated (1h at 37 C) with
60ml of Avidin-HRP diluted 1 : 10000. Peroxidase-catalyzed color de-
velopment from o-phenylenediamine was measured at 492nm [28].
Competition experiments were performed coating the wells with
0.5mg of HDL diluted as described earlier. A mixture of Hpt (0.9mM)
with acetylated peptides embedded into proteoliposomes (1, 5, 10,
20 or 30mM peptide concentration) in CB-TBS buffer (5mM CaCl2,
0.2% BSA, 130mM NaCl, 20mM Tris-HCl, pH7.3) was kept for 2h at
37 C and then incubated in the wells (2 h, 37 C). Hpt binding was
detected by treatment with 60ml of rabbit anti-Hpt IgG (1 : 2000
dilution T-TBS containing 0.25% BSA; 1h, 37 C) followed by goat
anti-rabbit horseradish peroxidase-conjugated-linked IgG (1 : 4000
dilution, 1h, 37 C). Color development was monitored at 492nm.
Absorbance values were converted to the percentage of Hpt binding
in the absence of acetylated peptide.
The acetylated P2a, Apo146, and Apo157 peptides were embed-
ded into proteoliposomes (peptide/lecithin/cholesterol, 1.5 : 200 :
18 molar ratio) prepared by the cholate dialysis technique [27]. In
detail, egg lecithin in ethanol was mixed with cholesterol in ethanol,
into a glass vial. The solvent was evaporated under nitrogen stream
and to the dried lipids, Tris-saline (85mM sodium cholate, 150mM
NaCl, 10mM Tris-HCl, pH8) was added. After vigorous whirling, the
micelle suspension was incubated (90min, 37 C) and repeatedly
shaken until clear. Then, peptide was added to the lipid suspension,
which was further incubated for 1h at 37 C. The resulting
proteoliposome suspension was extensively dialyzed against TBE
(140mM NaCl, 1mM EDTA, 10mM Tris–HCl, pH7.3), at 4 C, to
remove cholate.wileyonlinelibrary.com/journal/jpepsci Copyright © 2013 European PeThe molarity of Hpt (mixed phenotypes) was expressed as
concentration of monomer, that is, the unit containing one
subunit b (40 kDa) and one subunit a (a1, 8.9 kDa, or a2, 16 kDa)
[10,13].
LCAT assay
A pool of plasma samples, treated with 0.65% DS (MW=50kDa) in
0.2M CaCl2 to remove lipoproteins, was used as source of LCAT
(DS-treated plasma). The enzyme activity was measured using a
proteoliposome (ApoA-I/lecithin/cholesterol = 1.5 : 200 : 8 molar
contribution) as substrate, essentially according to published
procedures [23]. Control assays were performed without Hpt and
peptides, or in presence of Hpt. The proteoliposome was prepared
by the cholate dialysis technique [29]. In detail, 8ml of 50mg/ml
egg lecithin in ethanol were mixed with 18ml of 1mg/ml cholesterol
in ethanol, 40ml of [1,2-3H(N)]-cholesterol (1mCi/ml) into a glass vial.
The solvent was carefully evaporated under nitrogen stream at room
temperature, and to the dried lipids, 170ml of a suspension medium
(85mM sodium cholate, 150mM NaCl, 10mM Tris–HCl, pH8) was
added. After vigorous whirling (3min, room temperature), the
micelle suspension was incubated (90min, 37 C) and repeatedly
shaken every 10min until clear. Then, 90ml of 1.20mg/ml ApoA-I
was added to the lipid suspension, which was further incubated for
1h at 37 C. The resulting proteoliposome suspension was extensively
dialyzed against TBE (140mM NaCl, 1mM EDTA, 10mM Tris–HCl,
pH7.3), at 4 C, to remove cholate. The dialyzed volume was adjusted
to 285ml using TBE. The reaction mixture (1ml ﬁnal volume) was
prepared by putting together 697ml of TBE containing 5mM CaCl2,
83ml of 6% human serum albumin, and 160ml of proteoliposome
suspension (diluted 1 : 20 in TBE) into a screw-capped tube and
heating at 38 C for 30min. The assay was carried out by addition of
2.5ml of 2mM b-mercaptoethanol and 3.5ml of DS-treated plasma to
100ml of reaction mixture, which was rapidly divided into three
aliquots of 32ml and incubated (1h, 37 C). The reaction was stopped
by addition of 130ml of ethanol to each aliquot. The lipids were
extracted in 600ml of hexane, containing 10mg/ml cholesterol and
10mg/ml cholesteryl linoleate. After recovering the organic phase,
the aqueous phase was again treated with 500ml of the extraction
solution (twice), and the three extracts were pooled. Hexane was
removed under nitrogen stream, and the dried lipids were dissolved
in 50ml of chloroform. Cholesteryl esters were separated from
cholesterol by thin layer chromatography, using petroleum ether,
diethyl ether, and acetic acid (90 : 30 : 1, v : v : v) as mobile phase.
The lipid spots were visualized under iodine vapor and recovered for
scintillation analysis. The enzyme activity was expressed in units (nmol
of cholesterol esteriﬁed/h/ ml of plasma).
Statistical Analysis
ELISA was carried out with three replicates. Samples in the LCAT
assay were analyzed in triplicate. The data were expressed as mean
value SEM. The programGraphPad Prism 5.01 (GraphPad Software,
San Diego, CA, USA) was used to evaluate signiﬁcance of statistical
differences by one-way ANOVA, followed by Tukey’s test for multiple
comparisons.
Results and Discussion
Peptides Design and Synthesis
In order to identify the P2a residues involved in Hpt recognition, we
designed a series of P2a analogs by varying the peptide length or byptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2013; 19: 220–226
Table 1. Amino acid sequence of P2a and alanine substituted
analogs
Peptide Sequence
P2a Ac-LSPLGEEMRDRARAHVDALRTHLA-NH2
Apo146 Ac-LSPLGAEMRDRARAHVDALRTHLA-NH2
Apo147 Ac-LSPLGEAMRDRARAHVDALRTHLA-NH2
Apo149 Ac-LSPLGEEMADRARAHVDALRTHLA-NH2
Apo150 Ac-LSPLGEEMRARARAHVDALRTHLA-NH2
Apo151 Ac-LSPLGEEMRDAARAHVDALRTHLA-NH2
Apo153 Ac-LSPLGEEMRDRAAAHVDALRTHLA-NH2
Apo155 Ac-LSPLGEEMRDRARAAVDALRTHLA-NH2
Apo157 Ac-LSPLGEEMRDRARAHVAALRTHLA-NH2
Apo160 Ac-LSPLGEEMRDRARAHVDALATHLA-NH2
Apo162 Ac-LSPLGEEMRDRARAHVDALRTALA-NH2
CHARACTERIZATION OF A HAPTOGLOBIN PEPTIDE BINDERintroducing single point mutations. In particular, peptide P2a
sequence, which reproduces ApoA-I 141–164 region, contains eight
charged residues and two histidines that are highly conserved
between species (Figure 1). We singularly replaced each of these
residues with alanine, in order to evaluate the contribution of the
side-chains to the binding to Hpt (Table 1). Furthermore, P2a was
truncated at both terminal sides to evaluate the minimal sequence
requirements for its bioactivity (Table 2).
Binding Analysis of P2a Analog Peptides to Hpt
In order to evaluate the minimal P2a sequence required for Hpt
binding, different amounts (0.3, 1, 3 or 10mM) of biotinylated
truncated peptides (Apo141-161, Apo144-164, and Apo146-164)
were loaded into Hpt-coated wells, and their efﬁciency of binding
to Hpt was compared with that of P2a by ELISA. As shown in Figure 2
(A), the peptide Apo144-164 boundHptwith efﬁciency similar to that
of P2a, when used at 0.3 or 1mM concentration and higher than P2a
(p< 0.01) when used at 3 or 10mM concentration. The deletion of
two more residues at the N-terminal of P2a (Apo146-164) resulted
in an evident drop of binding efﬁciency with respect to P2a at all
the assayed concentration. The C-terminal truncated peptide
Apo141-161 exhibited a binding efﬁciency lower than P2a (p< 0.01)
in the range 0.3–3mM and similar to P2a when used at 10mM
concentration. These results suggest that the ApoA-I sequence
144–164 is essential for the binding to Hpt.
In order to assess the Hpt binding contribution of charged
and histidine residues, ten conserved residues were replaced
with alanine (Table 1). The biotinylated peptides were separately
incubated in Hpt-coated wells and Avidin-HRP was used to detect
their binding to Hpt. The analysis of the peptide binding to Hpt
showed that replacement with alanine is not detrimental. In
particular, the peptides with Glu146Ala (Apo146), Asp157Ala
(Apo157), or His162Ala (Apo162) substitutions showed a binding
efﬁciency to Hpt signiﬁcantly higher (p< 0.01) than P2a, at any
concentration used in the assay [Figure 2(B)]. Notably, this effect
was dose-dependent.
The results of the binding experiments suggest that charged and
histidine residues are not involved in Hpt recognition, and hydropho-
bic interactions play a major role in driving the binding. The increase
in binding efﬁciency of Apo146 and Apo157 peptides could reﬂect
the elimination of an unfavorable electrostatic interaction or the
stabilization of a more favorable conformation. Indeed, amino acidsFigure 1. Sequence alignment of ApoA-I 141–164 region from different
sources. Charged and histidine residues are highlighted in red.
J. Pept. Sci. 2013; 19: 220–226 Copyright © 2013 European Peptide Society areplacement with alanine, which has the highest intrinsic helix
propensity [30], may affect peptide helix content. The change in
binding efﬁciency could reﬂect a different ability of the peptide to
adopt the helical conformation in solution or when bound to Hpt,
as ApoA-I region 141–164 assumes a helical conformation in the
native protein.
Far-UV Circular Dichroism Analysis
The conformational properties of peptide P2a and its alanine analogs
were investigated by far-UV circular dichroism spectroscopy to
evaluate their propensity to adopt a helical secondary structure.
The CD spectra of peptides in phosphate buffer (Figure 3) are charac-
terized by a deep minimum around 200nm and shallow minimum
centered at 222nm. These spectra indicate that all the analyzed
peptides are predominantly in a random coil conformation with a
small percentage of helical structure in water solution. This result is
not surprising considering that amino acid sequences excised from
their natural context rarely adopt in water solution the native confor-
mation. In order to verify peptides propensity toward a helical
conformation, we performed a titration with TFE, a well-known
organic cosolvent able to stabilize a helical conformation in peptides
[31]. CD spectra of peptides were acquired increasing TFE volume
from 0% to 50% as it is well known that the TFE reaches its stabilizing
effect around the percentage of 40% of volume [32].
Increasing TFE volume all peptide spectra (Figure 3) showed a shift
toward 208nm and an increase of intensity of theminimum at lower
wavelength; contemporary, the intensity of the band at 222nm
signiﬁcantly increased. A crossover (around 200nm) and an
isodichroic (at 203nm) points were revealed in all titrations. The ratio
of ellipticity at 222 (θ222) and 208nm (θ208) was around the unity at
40% TFE for all peptides [33]. Furthermore, all peptides showed a
sigmoidal-like variation of the helical induction curve (data not
shown). These spectral characteristics are clearly indicative of a
transition from a random coil to an a-helical conformation. CDTable 2. Amino acid sequence of truncated P2a peptides
Peptide Sequence
P2a Ac-LSPLGEEMRDRARAHVDALRTHLA-NH2
Apo144-164 Ac-LGEEMRDRARAHVDALRTHLA-NH2
Apo146-164 Ac-EEMRDRARAHVDALRTHLA-NH2
Apo141-161 Ac-LSPLGEEMRDRARAHVDALRT-NH2
nd John Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
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Figure 3. Far-UV circular discroism analysis of P2a analogs. TFE titration spe
buffer with increasing volume of TFE from 0% to 50%. Spectra are reported
Figure 2. Binding of truncated (A) and P2a analogs (B) to Hpt. Different
concentrations (0.3, 1, 3, or 10mM) of biotinylated peptides were incubated
in Hpt-coated wells. Avidin-HRP was used to detect bound peptides. The sam-
ples were analyzed in triplicate and the data are expressed as mean SEM.
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4spectra of peptides in presence of 20% TFE almost showed the full
characteristics of a helical conformation.
Analysis of the TFE titration experiments showed that, although in
all analyzed peptides, the helical conformation is scarcely populated
in water solution, all peptide analogs are able to assume a helical
conformation in a water/TFE solution. On the basis of CD experi-
ments, we can conclude that alanine replacement does not signiﬁ-
cantly modify the conformational properties of P2a peptide analogs;
hence, the different Hpt binding efﬁciency should be attributed to
side-chain replacement. In particular, all P2a analogs showed a
comparable binding efﬁciency with respect to P2a except for
Apo146 and Apo157 peptides. We can speculate that when P2a
binds to Hpt, it localizes the side chain of Glu146 and Asp157 close
to two negative charged regions that interact unfavorable with
Glu146 and Asp157 side chains.Competition of Peptides (P2a, Apo146, and Apo157) with
HDL for Binding Hpt
In order to investigate the biological properties of the two P2a
analogs with the highest Hpt binding efﬁciency (Apo146 and
Apo157), the ability of Apo146 and Apo157 to inﬂuence the Hpt
binding to HDL was evaluated in vitro and compared with that of
P2a. HDL-coated wells were incubated with Hpt in the absence or
presence of different amounts (1–30mM) of each acetylated peptide
(P2a, Apo146, or Apo157), and the amount of HDL-bound Hpt was
measured. The three peptides, at concentration higher than 1mM,
signiﬁcantly impaired Hpt binding to HDL (p< 0.0001). Interestingly,
the inhibition of Hpt binding to HDL by Apo157 was higher than
those of P2a and Apo146, at any assayed concentration (p< 0.0001).
In particular, as shown in Figure 4, P2a and Apo146 displaced up to
about 55% of Hpt from binding HDL (p< 0.0001), with no difference
between them, at any assayed concentration, whereas the peptide
Apo157 was able to displace up to 65% of Hpt (p< 0.0001). Thesectra of P2a peptide analogs were acquired at 20 C in 10mM phosphate
as molar residue ellipticity.
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Figure 4. Peptide competition with HDL for binding Hpt. Hpt (0.9mM)
was incubated for 2 h at 37 C with acetylated P2a (full squares), or
Apo146 (open squares) or Apo157 (open triangles) (0–30mM). Aliquots
were then incubated in HDL-coated wells (2 h, 37 C). Hpt binding to
HDL was detected by rabbit anti-Hpt IgG and GAR-HRP IgG. The amount
of immunocomplexes was determined by measuring the absorbance at
492 nm. Data are reported as percent of the value obtained by incubation
of Hpt alone (open circle) and expressed as mean SEM.
CHARACTERIZATION OF A HAPTOGLOBIN PEPTIDE BINDERresults suggest that the Asp157Ala substitution in the P2a sequence
improves the binding of the peptide to Hpt.
LCAT Inhibition by Hpt: Effect of P2a or Apo146 or Apo157
The ability of the peptides to compete with ApoA-I for binding Hpt
was also evaluated in LCAT activity assay. DS-treated plasma and
labeled proteoliposomes (LCAT and ApoA-I-containing cholesterol
sources, respectively) were incubated with 0.4mM Hpt, in the
absence or presence of different amounts (0.8 or 1.2mM) of each
peptide. The LCAT activity was signiﬁcantly reduced (about 74%)
by Hpt (5.42 0.12 units versus 1.47 0.02 units; p< 0.0001) but
differently restored when peptides were present during incubation
(Figure 5), with Apo146 and Apo157 being more effective than P2a
(p< 0.0001) in rescuing the enzyme activity. In particular, the useFigure 5. Effect of peptides on the inhibition of LCAT activity by Hpt. The
LCAT activity was assayed in absence or presence of 0.4mM Hpt and different
amounts (0.8 or 1.2mM) of P2a or Apo146 or Apo157. A pool of plasma
samples (treated with 0.65% dextran sulfate, MW=50kDa, in 0.2M CaCl2 to
remove lipoproteins) was used as source of LCAT, whereas a proteoliposome
(ApoA-I/lecithin/3H-cholesterol, 1.5 : 200 : 18 molar ratio) was used as
substrate. The LCAT activity is expressed in units corresponding to nmol of
cholesterol incorporated per hour per ml of plasma. Samples were analyzed
in triplicate, and data are expressed as means SEM.
J. Pept. Sci. 2013; 19: 220–226 Copyright © 2013 European Peptide Society aof 0.8mM (peptide/Hpt molar ratio 2:1) of Apo146 or Apo157 in the
assay restored about 70% of the LCAT activity, with no difference
between the two peptides, whereas P2a, at this concentration,
restored 50% of the LCAT activity, thus conﬁrming that amino acid
changes in P2a sequence inﬂuence the afﬁnity of the peptide for
Hpt. The three peptides fully saved the enzyme stimulation by
ApoA-I, when used at 1.2mM concentration in the assay (peptide/
Hpt molar ratio 4 : 1). The peptides, when incubated without Hpt,
did not signiﬁcantly affect the cholesterol esteriﬁcation (data not
shown).2
2
5Conclusions
P2a peptide sequence was modiﬁed in order to analyze the molec-
ular determinants of Hpt binding. Analysis of truncated P2a analogs
showed that P2a sequence can only be slightly reduced in length at
the N-terminal, without altering the ability of binding to Hpt. In
particular, the deletion of the dipeptide Leu144-Gly145 drastically
reduces the binding to Hpt, suggesting an important role of
hydrophobic interactions. Furthermore, the role of charged
residues was systematically analyzed by replacing them with
alanine. Binding assays showed that charged residues are not
involved in Hpt recognition; actually, E146A e D157A substitutions
increase the binding afﬁnity to Hpt. Biological characterization of
the corresponding P2a peptide analogs, Apo146 and Apo157,
showed that the two peptides are more effective than P2a in
rescuing the LCAT activity from Hpt inhibition. This result suggests
novel hints to design peptides with anti-atherogenic activity, which,
displacing Hpt from HDL, might rescue LCAT activity and improve
reverse cholesterol transport.
References
1 Sorci-Thomas MG, Thomas MJ. The effects of altered apolipoprotein
A-I structure on plasma HDL concentration. Trends Cardiovasc. Med.
2002; 12: 121–128.
2 Davidson WS, Thompson TB. The structure of apolipoprotein A-I in
high density lipoproteins. J. Biol. Chem. 2007; 282: 22249–22253.
3 Thomas MJ, Bhat S, Sorci-Thomas MG. Three-dimensional models of
HDL apoA-I: implications for its assembly and function. J. Lipid Res.
2008; 49: 1875–1883.
4 Wu Z, Gogonea V, Lee X, Wagner MA, Li XM, Huang Y, Undurti A, May
RP, Haertlein M, Moulin M, Gutsche I, Zaccai G, Didonato JA and Hazen
SL. Double superhelix model of high density lipoprotein. J. Biol. Chem.
2009; 284: 36605–36619.
5 Mei X, Atkinson D. Crystal structure of C-terminal truncated apolipo-
protein A-I reveals the assembly of high density lipoprotein (HDL)
by dimerization. J. Biol. Chem. 2011; 286: 38570–38582.
6 Huang R, Silva RA, Jerome WG, Kontush A, Chapman MJ, Curtiss LK,
Hodges TJ, Davidson WS. Apolipoprotein A-I structural organization
in high-density lipoproteins isolated from human plasma. Nat. Struct.
Mol. Biol. 2011; 18: 416–422.
7 Wu Z, Gogonea V, Lee X, May RP, Pipich V, Wagner MA, Undurti A, Tallant
TC, Baleanu-Gogonea C, Charlton F, Ioffe A, Di Donato JA, Rye KA, Hazen
SL. The low resolution structure of ApoA1 in spherical high density
lipoprotein revealed by small angle neutron scattering. J. Biol. Chem.
2011; 286: 12495–124508.
8 Sevugan Chetty P, Mayne L, Kan ZY, Lund-Katz S, Englander SW,
Phillips MC Apolipoprotein A-I helical structure and stability in
discoidal high-density lipoprotein (HDL) particles by hydrogen
exchange and mass spectrometry. Proc. Natl. Acad. Sci. U.S.A. 2012;
109: 11687–11692.
9 Balestrieri M, Cigliano L, De Simone ML, Dale B, Abrescia P. Haptoglobin
inhibits lecithin-cholesterol-acyltrasferase in human ovarian follicular ﬂuid.
Mol. Reprod. Dev. 2001; 59: 186–191.
10 Spagnuolo MS, Cigliano L, Abrescia, P. The binding of haptoglobin to
apolipoprotein A-I: inﬂuence of hemoglobin and concanavalin A. Biol.
Chem. 2003; 384: 1593–1596.nd John Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
SPAGNUOLO ET AL.
2
2
611 Giblett ER. The haptoglobin system. Ser. Haematol. 1968; 1: 3–20.
12 Nagel RL, Gibson QH. The binding of Hemoglobin to Haptoglobin and
its relation to subunit dissociation of Hemoglobin. J. Biol. Chem. 1971,
246: 69–73.
13 Langlois MR, Delanghe JR. Biological and clinical signiﬁcance
of haptoglobin polymorphism in humans. Clin. Chem. 1996;
42: 1589–1600.
14 Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ,
Law SK, Moestrup SK Identiﬁcation of the haemoglobin scavenger
receptor. Nature 2001; 409: 198–201.
15 Gutteridge JMC. The antioxidant activity of haptoglobin towards
haemoglobin-stimulated lipid peroxidation. Biochim. Biophys. Acta
1987; 917: 219–223.
16 Alayash AI. Redox biology of blood. Antioxid. Redox Signal. 2004;
6: 941–949.
17 Salvatore A, Cigliano L, Bucci EM, Corpillo D, Velasco S, Carlucci A,
Pedone C, Abrescia P. Haptoglobin binding to apolipoprotein A-I
prevents damage from hydroxyl radicals on its stimulatory activity
of the enzyme lecithin-cholesterol acyl-transferase. Biochemistry
2007; 46: 1158–1168.
18 Cigliano L, Pugliese CR, Spagnuolo MS, Palumbo R, Abrescia P.
Haptoglobin binds the antiatherogenic protein apolipoprotein
E - impairment of apolipoprotein E stimulation of both lecithin:
cholesterol acyltransferase activity and cholesterol uptake by
hepatocytes. FEBS J. 2009; 276: 6158–6171.
19 Braeckman L, De Bacquer D, Delanghe J, Claeys L, De Backer G.
Associations between haptoglobin polymorphism, lipids, lipoproteins
and inﬂammatory variables. Atherosclerosis 1999; 143: 383–388.
20 De Bacquer D, De Backer G, Langlois M, Delanghe J, Kesteloot H,
Kornitzer M. Haptoglobin polymorphism as a risk factor for coronary
heart disease mortality. Atherosclerosis 2001; 157: 161–166.
21 Matuszek MA, Aristoteli LP, Bannon PG, Hendel PN, Hughes CF, Jessup
W, Dean RT, Kritharides L. Haptoglobin elutes from human atheroscle-
rotic coronary arteries--a potential marker of arterial pathology.
Atherosclerosis 2003; 168: 389–396.
22 Sorci-Thomas MG, Curtiss L, Parks JS, Thomas MJ, Kearns MW,
Landrum M. The hydrophobic face orientation of apolipoprotein A-I
amphipathic helix domain 143–164 regulates lecithin: cholesterol
acyltransferase activation. J. Biol. Chem. 1998; 273: 11776–11782.wileyonlinelibrary.com/journal/jpepsci Copyright © 2013 European Pe23 Spagnuolo MS, Cigliano L, D’Andrea LD, Pedone C, Abrescia P
Assignment of the binding site for haptoglobin on apolipoprotein
A-I. J. Biol. Chem. 2005; 280: 1193–1198.
24 Bucci M, Cigliano L, Vellecco V, D’Andrea LD, Ziaco B, Rossi A, Sautebin
L, Carlucci A, Abrescia P, Pedone C, Ianaro A, Cirino G. Apolipoprotein
A-I (ApoA-I) mimetic peptide P2a by restoring cholesterol esteriﬁca-
tion unmasks ApoA-I anti-inﬂammatory endogenous activity in vivo.
J. Pharmacol. Exp. Ther. 2012; 340: 716–722.
25 Bradford MM. A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-
dye binding. Anal. Biochem. 1976; 72: 248–254.
26 Cigliano L, Spagnuolo MS, Abrescia P Quantitative variations of the
isoforms in haptoglobin 1-2 and 2-2 individual phenotypes. Arch.
Biochem. Biophys. 2003; 416: 227–237.
27 Cigliano L, D’Andrea LD, Maresca B, Serino M, Carlucci A, Salvatore A,
Spagnuolo MS, Scigliuolo G, Pedone C, Abrescia P. Relevance of the
amino acid conversions L144R (Zaragoza) and L159P (Zavalla) in the
apolipoprotein A-I binding site for haptoglobin. Biol. Chem. 2008;
389: 1421–1426.
28 Porta A, Cassano E, Balestrieri M, Bianco M, Picone R, De Stefano C,
Abrescia P. Haptoglobin transport into human ovarian follicles and
its binding to apolipoprotein A-I. Zygote 1999; 7: 67–77.
29 Chen C-H, Albers JJ. Characterization of proteoliposomes containing
apoprotein A-I: a new substrate for the measurement of lecithin:
cholesterol acyltransferase activity. J. Lipid Res. 1982; 23: 680–691.
30 DeGradoWF, Summa CM, Pavone V, Nastri F, Lombardi A. De novo design
and structural characterization of proteins andmetalloproteins. Annu. Rev.
Biochem. 1999; 68: 779–819.
31 Luo P, Baldwin RL. Mechanism of helix induction by triﬂuoroethanol: a
framework for extrapolating the helix-forming properties of peptides
from triﬂuoroethanol/water mixtures back to water. Biochemistry
1997; 36: 8413–8421.
32 Rohl CA, Chakrabartty A, Baldwin RLHelix propagation andN-cappropensities
of the amino acidsmeasured in alanine-based peptides in 40 volume percent
triﬂuoroethanol. Protein Sci. 1996; 5: 2623–2637.
33 Vuilleumier S, Mutter M. Synthetic peptide and template-assembled
synthetic protein models of the hen egg white lysozyme 87–97 helix:
importance of a protein-like framework for conformational stability in
a short peptide sequence. Biopolymers 1993; 33: 389–400.ptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2013; 19: 220–226
